Tens of Thousands of Heart Attacks Could Be Prevented With Better Statin Adherence

How Many Heart Attacks Could Statins Prevent If Used According to Guidelines?

Research from the Johns Hopkins Bloomberg School of Public Health has quantified the enormous cardiovascular toll of underusing cholesterol-lowering medications. The analysis found that if statins and other lipid-lowering drugs were prescribed and taken according to established clinical guidelines — such as those from the American College of Cardiology and American Heart Association — a substantial number of heart attacks and strokes that currently occur each year in the United States could be prevented.

The gap between guidelines and practice is well-documented. According to data from the CDC, heart disease remains the leading cause of death in the United States, responsible for approximately 700,000 deaths annually. Statins, the most widely prescribed class of cholesterol-lowering drugs, have decades of evidence supporting their ability to reduce LDL cholesterol by up to 50% and lower the risk of major cardiovascular events. Yet studies consistently show that many eligible patients either never receive a prescription or discontinue therapy within the first year.

Why Are So Many Patients Not Taking Cholesterol-Lowering Medications?

Multiple factors contribute to the underuse of statins and related therapies. On the prescribing side, research suggests that many patients who meet guideline criteria for lipid-lowering treatment — particularly those at intermediate cardiovascular risk — are never offered medication. Primary care physicians may underestimate a patient's risk or prioritize lifestyle modifications alone, even when guidelines recommend pharmacotherapy alongside diet and exercise changes.

From the patient perspective, concerns about side effects — particularly muscle pain, which studies suggest affects roughly 5–10% of users — lead many to discontinue therapy. Misinformation about statins, including exaggerated fears circulated on social media, compounds the problem. The World Health Organization has identified medication non-adherence as a major global health challenge, estimating that adherence to long-term therapies in developed countries averages only about 50%. For statins specifically, multiple studies have documented that nearly half of patients stop taking the medication within one year of initiation.

What Should Patients and Doctors Do to Close the Treatment Gap?

The Johns Hopkins findings reinforce calls from leading cardiology organizations to improve both the initiation and continuation of evidence-based lipid-lowering therapy. The American Heart Association recommends that clinicians use validated risk calculators to identify patients who would benefit from statin therapy and engage in shared decision-making conversations that address patient concerns honestly. For patients who experience genuine side effects, alternative statins, lower doses, or newer agents such as PCSK9 inhibitors and bempedoic acid may offer effective alternatives.

Health systems can also play a role through automated reminders, pharmacist-led medication management programs, and reducing cost barriers. Generic statins are now widely available at low cost, removing a significant historical obstacle to adherence. Public health experts emphasize that even modest improvements in guideline adherence across the population could translate into thousands of prevented heart attacks and strokes each year — a meaningful reduction in the nation's leading cause of death and disability.